Epoxomicin, 20S proteasome inhibitor (ab144598)
Key features and details
- Potent, selective, irreversible and cell-permeable 20S proteasome inhibitor
- CAS Number: 134381-21-8
- Purity: > 97%
- Soluble in DMSO to 10 mM
- Form / State: Solid
- Source: Actinomyces sp.
製品の概要
-
製品名
Epoxomicin, 20S proteasome inhibitor -
製品の詳細
Potent, selective, irreversible and cell-permeable 20S proteasome inhibitor -
生理活性の詳細
Potent, selective, irreversible and cell-permeable 20S proteasome inhibitor (IC50 = 4 nM). Predominantly inhibits the chymotrypsin-like activity. Anti-inflammatory and antitumor agent. Active in vitro and in vivo. -
精製度
> 97% -
CAS 番号
134381-21-8 -
構造式
製品の特性
-
体系名
N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide -
分子量
554.73 -
分子式
C28H50N4O7 -
PubChem 登録番号
3035402 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 10 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CCC(C)C(C(=O)NC(=O)C(C(C)O)NC(CC(C)C)C(=O)C1(CO1)C)NC(=O)C(C(C)CC)N(C)C(=O)C -
由来
Actinomyces sp.
-
研究分野
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (4)
ab144598 は 4 報の論文で使用されています。
- Cassioli C et al. The Bardet-Biedl syndrome complex component BBS1 controls T cell polarity during immune synapse assembly. J Cell Sci 134:N/A (2021). PubMed: 34423835
- Cassioli C et al. The Bardet-Biedl syndrome complex component BBS1 controls T cell polarity during immune synapse assembly. J Cell Sci N/A:N/A (2021). PubMed: 34251457
- Ren D et al. Wnt5a induces and maintains prostate cancer cells dormancy in bone. J Exp Med 216:428-449 (2019). PubMed: 30593464
- Onnis A et al. The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II. Autophagy 14:2117-2138 (2018). PubMed: 30109811